X4 Pharma Files DEF 14A: Executive Comp & Governance
Ticker: XFOR · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
X4 Pharma's DEF 14A is out, showing exec pay details for 2024. Governance stuff.
AI Summary
X4 Pharmaceuticals, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation and corporate governance matters. The filing covers the fiscal year ending December 31, 2024, and includes information on equity awards granted to principal executive officers (PEOs) and non-PEO/NEOs. The company, formerly known as Arsanis, Inc., is based in Boston, MA.
Why It Matters
This filing provides insight into how X4 Pharmaceuticals compensates its top executives and the structure of its board, which can influence strategic decisions and shareholder value.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but they can reveal information about executive compensation and corporate governance that may impact investor confidence and stock performance.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for compensation details)
- 20250425 — Filing Date (Date the DEF 14A was submitted)
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Filer
- Arsanis, Inc. (company) — Former Company Name
- 0001501697 (company) — Central Index Key
- 273181608 (company) — EIN
- 61 NORTH BEACON STREET (company) — Business Address
- BOSTON (company) — Business City
- MA (company) — Business State
- 02134 (company) — Business Zip Code
- 857-529-8300 (company) — Business Phone
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors, executive compensation, and other corporate actions.
What fiscal year does this DEF 14A filing cover?
This DEF 14A filing covers the fiscal year ending December 31, 2024.
What was X4 Pharmaceuticals, Inc. formerly known as?
X4 Pharmaceuticals, Inc. was formerly known as Arsanis, Inc.
Where is X4 Pharmaceuticals, Inc. headquartered?
X4 Pharmaceuticals, Inc. is headquartered at 61 North Beacon Street, 4th Floor, Boston, MA 02134.
What type of information is typically found in the 'ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember' sections?
These sections typically detail the year-end fair value of equity awards granted in the covered year that are outstanding and unvested for different groups of employees, such as Principal Executive Officers (PEOs) and Non-PEO/NEOs.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding X4 Pharmaceuticals, Inc (XFOR).